cas 1865-83-4|| where to buy 7-Methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one

Nombre del producto:7-Methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one

IUPAC Name:7-methoxy-1,1-dimethyl-1,2,3,4-tetrahydronaphthalen-2-one

: CAS：1865-83-4; Fórmula molecular：C13H16O2; Pureza：95%

: Número de catálogo：CM140627; Peso molecular：204.27

Unidad de embalaje	Stock disponible	Precio($)
CM140627-250mg	in stock	ƃǫ
CM140627-1g	in stock	ŪȅŞ

Consulta: sales@chemenu.com

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Notas adicionales

Verification code*

refresh

Detalles del producto

: Núm. De CAS :1865-83-4; Fórmula molecular:C13H16O2; Punto de fusión:-; Código de sonrisas:O=C1C(C)(C)C2=C(C=CC(OC)=C2)CC1; Densidad:

: Número de catálogo:CM140627; Peso molecular:204.27; Punto de ebullición:; Nº Mdl:MFCD20274514; Almacenamiento:

Category Infos

: Naphthalenes; Naphthalene is a hydrocarbon produced by the distillation of coal tar and is an aromatic white crystalline substance. Naphthalene is the most abundant component in coal tar. It is used as an insect repellant and insect fumigant. The compound is used in the manufacture of celluloid, dyes, hydrogenated naphthalenes, oil fumes, smokeless powders and synthetic resins.

Column Infos

: Naphthalenes

: Alectinib; Genentech, a member of the Roche Group, has announced that its ALK inhibitor Alecensa® (Alectinib) met its primary endpoint of disease-free survival (DFS) at a scheduled interim analysis of the phase 3 ALINA trial. Alecensa as adjuvant therapy resulted in statistically significant DFS and clinically meaningful improvement.
Worldwide, lung cancer is one of the most common cancers, with NSCLC accounting for 80% to 85% of all lung cancer cases. Despite adjuvant chemotherapy, about half of patients with early-stage lung cancer experience cancer recurrence after surgery. Recent therapeutic innovations, including immunotherapy, have improved the outlook for some patients with early-stage NSCLC; however, there are currently no ALK inhibitors approved for early-stage ALK-positive disease. Alecensa is the first ALK inhibitor proven in a Phase 3 trial to reduce the risk of disease recurrence or death in patients with early-stage ALK-positive NSCLC.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products

529-33-9

341-41-3

573-97-7

2472-22-2

771-15-3

22009-38-7

10420-89-0

16712-64-4

3082-62-0

1141-38-4

13214-70-5

3886-70-2

3906-16-9

3400-33-7

7442-52-6

20717-80-0

960009-55-6

23981-47-7

22009-37-6

2631-61-0

1590-08-5

26673-32-5

63449-68-3

18531-94-7

132095-54-6

13672-07-6

39110-32-2

13185-18-7

2752-87-6

1013-04-3

40604-49-7

78119-82-1

613-17-2

90162-14-4

530-93-8

481-42-5

529-34-0

604-53-5

63785-44-4

871731-74-7

41823-28-3

118693-55-3

51793-09-0

7480-36-6

318-98-9

522-48-5

68449-30-9

1201-74-7

317-79-3

26231-23-2

204530-94-9

2437-16-3

81-86-7

23979-41-1

52927-22-7

130-13-2

2976-75-2

61551-49-3

40675-81-8

21331-43-1

13949-67-2

10470-82-3

30366-94-0

7756-78-7

43038-45-5

5341-58-2

39627-84-4

438531-00-1

56503-96-9

351156-65-5

350997-17-0

351156-60-0

350997-18-1

42882-31-5

52373-02-1

832-89-3

22302-58-5

7732-44-7

7248-26-2

438472-54-9

24310-15-4

36304-47-9

143540-88-9

438219-62-6

438219-93-3

10151-46-9

183111-59-3

443864-73-1

93-36-7

23204-36-6

14233-73-9

15100-93-3

773-99-9

41790-30-1

1592-38-7

198287-32-0

133690-96-7

2006278-33-5

90-15-3

15231-91-1

582-17-2

116230-30-9

1125-78-6

131-91-9

607-24-9

2033-42-3

52727-28-3

571-57-3

569-42-6

117-59-9

82957-06-0

57944-44-2

604-44-4

7469-77-4

948-03-8

135-76-2

35689-26-0

144876-33-5

20816-78-8

16149-05-6

23357-46-2

1261732-17-5

1743-01-7

2241-98-7

39110-74-2

14489-75-9

185669-79-8

23357-52-0

2298-07-9

771-14-2

104484-71-1

7499-66-3

479-27-6

2216-68-4

438-32-4

438-26-6

1261808-45-0

131707-40-9

1241377-74-1

4766-33-0

607-23-8

16452-11-2

63240-26-6

1337523-99-5

13916-98-8

13802-40-9

156390-35-1

2017-68-7

324-42-5

31846-36-3

3880-78-2

389104-55-6

41791-59-7

606-57-5

651735-61-4

6134-55-0

61495-10-1

6315-96-4

65440-41-7

67886-69-5

70504-01-7

71590-31-3

72016-73-0

72019-91-1

84460-89-9

86217-42-7

843644-23-5

21032-12-2

269066-75-3

2979-69-3

30236-02-3

3147-58-8

32908-40-0

315-53-7

315-56-0

37436-34-3

457065-49-5

51062-76-1

51981-66-9

575-08-6

56804-95-6

573-04-6

1093739-87-7

76673-34-2

90401-85-7

92297-66-0

93189-18-5

13101-89-8

2472-13-1

1590-25-6

198226-63-0

130200-58-7

13577-40-7

140377-92-0

13686-49-2

13686-51-6

145485-31-0

144464-64-2

15297-33-3

1634-09-9

160693-12-9

16208-20-1

173471-71-1

1680-51-9

20933-24-8

22272-22-6

93-12-9

2954-50-9

341-92-4

77060-74-3

91307-40-3

93742-85-9

535935-61-6

6843-89-6

727-49-1

82238-92-4

85858-95-3

4711-67-5

5247-86-9

53526-25-3

52218-35-6

53732-47-1

50402-56-7

58349-17-0

58596-07-9

62012-54-8

21880-87-5

137848-28-3

137848-29-4

103030-73-5

91271-31-7

90767-01-4

118201-38-0

94134-18-6

1032959-73-1

103860-60-2

1081-32-9

1220039-98-4

89781-52-2

13772-63-9

138113-07-2

309752-65-6

340825-13-0

32721-21-4

4003-89-8

32178-63-5

5419-82-9

65844-56-6

63823-26-7

67247-13-6

87491-79-0

887574-80-3

110931-79-8

86539-78-8

19125-84-9

51529-97-6

110808-69-0

19634-89-0

481-85-6

57536-86-4

737-89-3

92050-16-3

103987-83-3